{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:01:28Z","timestamp":1790740888872,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ceftazidime-avibactam (CAZ-AVI) is a recently approved \u03b2-lactam\u2013\u03b2-lactamase inhibitor combination with the potential to treat serious infections caused by carbapenem-resistant organisms. Few patients with such infections were included in the CAZ-AVI clinical trials, and clinical experience is lacking. We present a case series of patients with infections caused by carbapenem-resistant\n                    <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n                    (CRE) or\n                    <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n                    (CRPa) who were treated with CAZ-AVI salvage therapy on a compassionate-use basis. Physicians who had prescribed CAZ-AVI completed a case report form. We used descriptive statistics to summarize patient characteristics and treatment outcomes. We used the Wilcoxon rank sum test and Fisher's exact test to compare patients by treatment outcome. The sample included 36 patients infected with CRE and two with CRPa. The most common infections were intra-abdominal. Physicians categorized 60.5% of patients as having life-threatening infections. All but two patients received other antibiotics before CAZ-AVI, for a median of 13 days. The median duration of CAZ-AVI treatment was 16 days. Twenty-five patients (65.8%) concurrently received other antibiotics to which their pathogen was nonresistant\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Twenty-eight patients (73.7%, 95% confidence interval [CI], 56.9 to 86.6%) experienced clinical and\/or microbiological cure. Five patients (20.8%) with documented microbiological cure died, whereas 10 patients (71.4%) with no documented microbiological cure died (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.01). In three-quarters of cases, CAZ-AVI (alone or combined with other antibiotics) cured infections caused by carbapenem-resistant organisms, 95% of which had failed previous therapy. Microbiological cure was associated with improved survival. CAZ-AVI shows promising clinical results for infections for which treatment options are limited.\n                  <\/jats:p>","DOI":"10.1128\/aac.01964-16","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T21:31:07Z","timestamp":1480368667000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":170,"title":["Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms"],"prefix":"10.1128","volume":"61","author":[{"given":"Elizabeth","family":"Temkin","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Torre-Cisneros","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"},{"name":"Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica, Universidad de C\u00f3rdoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana","family":"Beovic","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, University Medical Center Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Benito","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Institut d'Investigaci\u00f3 Biom\u00e8dica Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Gilarranz","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Jeremiah","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St Vincent's Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Loeches","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Machuca","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"},{"name":"Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica, Universidad de C\u00f3rdoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Jim\u00e9nez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Critical Care Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic, IDIBAPS, Barcelona University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mora-Rillo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Navas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Osthoff","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Pozo","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Ramos Ramos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Critical Care Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Wolff","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Bichat-Claude Bernard, AP-HP, Paris, France"},{"name":"Universit\u00e9 Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Carmeli","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"FDA approves new antibacterial drug Avycaz","author":"U.S. Food and Drug Administration","year":"2015","unstructured":"U.S. Food and Drug Administration. 26February2015. FDA approves new antibacterial drug Avycaz. FDA news release. U.S. FDA, Silver Spring, MD. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm435629.htm . Accessed 13 September 2016."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-15"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.06.008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01559-15"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_2_13_2","volume-title":"\u03b2-Lactamase characterization of baseline Enterobacteriaceae (ENT) from a phase 3 trial of ceftazidime-avibactam (CAZ-AVI) for the treatment of infections caused by CAZ-nonsusceptible (NS) pathogens, abstr 1176","author":"Mendes RE","year":"2015","unstructured":"Mendes RE CastanheiraM WoosleyLN CostelloSE StoneGG FlammRK JonesRN. 2015. \u03b2-Lactamase characterization of baseline Enterobacteriaceae (ENT) from a phase 3 trial of ceftazidime-avibactam (CAZ-AVI) for the treatment of infections caused by CAZ-nonsusceptible (NS) pathogens, abstr 1176. Abstr IDWeek 2015, , San Diego, CA. https:\/\/idsa.confex.com\/idsa\/2015\/webprogram\/Paper53048.html. Accessed 13 September 2016."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku432"},{"key":"e_1_3_2_15_2","volume-title":"Avycaz package insert","author":"Actavis","year":"2015","unstructured":"Actavis. 2015. Avycaz package insert. Actavis, Parsippany, NJ. http:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi. Accessed 13 September 2016."},{"key":"e_1_3_2_16_2","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep62:165\u2013170.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_17_2","unstructured":"European Centre for Disease Prevention and Control. 2016. Antimicrobial resistance interactive database (EARS-Net). http:\/\/ecdc.europa.eu\/en\/healthtopics\/antimicrobial-resistance-and-consumption\/antimicrobial_resistance\/database\/Pages\/database.aspx. Accessed 13 September 2016."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01222-13"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ723"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01399-15"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00868-15"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01569-15"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00655-15"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154092"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.05.012"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03478.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2010.06.001"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv086"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02166-13"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks121"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S40698"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","author":"Shields RK","year":"2016","unstructured":"Shields RK PotoskiBA HaidarG HaoB DoiY ChenL PressEG KreiswirthBN ClancyCJ NguyenMH. 13September2016. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dispii: ciw636. Epub ahead of print.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-15"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw491"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.02.027"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L307"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4135"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1962.03620240029006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01964-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01964-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:39:51Z","timestamp":1645457991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01964-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1128\/AAC.01964-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01964-16","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727041846.793536919","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"2016-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01964-16"}}